Treatment for Factor V Leiden

Treatment Recommendations

For patients with Factor V Leiden, anticoagulation therapy should be determined based on clinical presentation, with indefinite anticoagulation recommended for homozygotes who have experienced a thrombotic event or heterozygotes with both Factor V Leiden and prothrombin 20210A mutations who have had thrombosis, as recommended by the American College of Medical Genetics and Genomics 1, 2
For Factor V Leiden homozygotes with a thrombotic event, indefinite (lifelong) anticoagulation therapy should be considered, according to the American College of Medical Genetics and Genomics 1, 2
For patients heterozygous for both Factor V Leiden and prothrombin 20210A mutation with thrombosis, indefinite therapy is suggested due to high recurrence risk, as stated by the American College of Medical Genetics and Genomics 1, 2, 4

The lifetime risk for venous thrombosis in Factor V Leiden heterozygotes is approximately 10%, while for homozygotes it exceeds 80%, according to the American College of Medical Genetics and Genomics 1, 2
There is no clear evidence that Factor V Leiden heterozygosity alone significantly increases risk of recurrent venous thrombosis, as reported by the American College of Medical Genetics and Genomics 1, 2, 6

For pregnant women with Factor V Leiden and recurrent pregnancy loss, antithrombotic therapy may be effective in allowing successful pregnancy outcomes, as suggested by the American College of Medical Genetics and Genomics 1
Women with Factor V Leiden should avoid combined oral contraceptives as they significantly increase thrombotic risk, according to the American College of Medical Genetics and Genomics 2

The risk of major bleeding with chronic warfarin therapy may reach 8% per year, which must be weighed against thrombosis risk, as reported by the American College of Medical Genetics and Genomics 1, 2
Regular reassessment of the risk/benefit ratio is essential for patients on long-term anticoagulation, as recommended by the American College of Medical Genetics and Genomics 2

Testing for Factor V Leiden should be considered in patients under age 50 with venous thrombosis, as recommended by the American College of Medical Genetics and Genomics 4
Testing for Factor V Leiden should be considered in patients with venous thrombosis in unusual sites (hepatic, mesenteric, cerebral veins), as suggested by the American College of Medical Genetics and Genomics 4
Testing for Factor V Leiden should be considered in patients with recurrent venous thrombosis, as recommended by the American College of Medical Genetics and Genomics 4
Testing for Factor V Leiden should be considered in patients with venous thrombosis and a strong family history of thrombotic disease, as suggested by the American College of Medical Genetics and Genomics 4